医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nitto’s ND-L02-s0201:RNAi Anti-Fibrosis Drug for the Treatment of Liver Fibrosis Granted FDA Fast Track Designation

2015年11月20日 PM11:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Japan’s leading diversified materials manufacturer Nitto Denko Corporation (TOKYO:6988)(ISIN:JP3684000007) reported preliminary results from their ongoing Phase1b/2 studies during The Liver Meeting® 2015, San Francisco. The Phase1b/2 clinical trial was designed to assess the safety, pharmacokinetics (PK), and biological activity of ND-L02-s0201, a targeted siRNA lipid nanoparticle (LNP), in patients with liver fibrosis. The interim results indicated that ND-L02-s0201 was well tolerated in advanced fibrosis patients and histological improvement of fibrosis was observed.

In addition, ND-L02-s0201 was granted two FDA Fast Track designations for both NASH and HCV liver fibrosis indications in October. Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Nitto continues to make significant efforts towards delivering new drugs for fibrosis and other intractable diseases to help patients in need.

With the brand slogan of “Innovation for Customers”, Nitto is committed to creating new value in the areas of Green (environment), Clean (new energy), and Fine (life sciences), looking forward to the company’s 100th anniversary in 2018 and beyond.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151120005187/en/

CONTACT

Nitto Denko Corporation
Toshiaki Minagawa / Rie Miura,
+81-6-7632-2101
Brand Strategy Dept., Corporate Strategy Management
Div.
FAX: +81-6-7632-2568
communication_group@nitto.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 美泰上市全球最先进的人参补剂
  • SpinalCyteが新たな日本国特許を取得
  • Together for Safer Roads任命 David Braunstein担任总裁
  • マシモ、rainbow®対応の多派長脈波変動指標となる非侵襲的RPVi™のCEマーク取得を発表
  • Masimo宣布rainbow®多波长脉搏灌注变异指数无创RPVi™获得CE标记